Search

Casey K Jager

from Bend, OR
Age ~46
Get Report
Also known as:
Casey Jager Living, Keith Jager Casey
Phone and address:
1830 NW Glassow Dr, Bend, OR 97703
Related to:
Nancy J Larsen, 41Alan Larsen, 71Jesse JagerBenton Markham, 45Danny L Desaulnier, 55
Connected to:
Amy Jager, 43Ben Jager, 56Cheryl Jager, 67David B Jager, 60Emily R Jager, 34Jacob R Jager, 50Jonathan W Jager, 36Kathleen L Jager, 81Laura F Jager, 38Linda Jager, 57

Casey Jager Phones & Addresses

  • 1830 NW Glassow Dr, Bend, OR 97703
  • 2168 Castle Ave, Bend, OR 97701 (541) 815-6812
  • 63314 Lavacrest St, Bend, OR 97701 (541) 617-0382
  • 21287 Thornhill Ln, Bend, OR 97701
  • Philomath, OR
  • Salem, OR
  • 4485 Airport Ave, Corvallis, OR 97333 (541) 754-7070
  • 2168 NE Castle Ave, Bend, OR 97701

Work

Position: Professional/Technical

Resumes

Resumes

Casey Jager Photo 1

Research Chemist

View page
Location:
Bend, OR
Industry:
Pharmaceuticals
Work:
Bend Research
Research Chemist
Education:
University of Oregon 2001 - 2002
Master of Science, Masters, Chemistry Willamette University 1997 - 2001
Bachelors, Bachelor of Science, Chemistry
Casey Jager Photo 2

Product Development Lead

View page
Work:
Lonza
Product Development Lead

Publications

Us Patents

Methods Of Manufacturing A Bifunctional Compound, Ultrapure Forms Of The Bifunctional Compound, And Dosage Forms Comprising The Same

View page
US Patent:
20230012321, Jan 12, 2023
Filed:
May 6, 2021
Appl. No.:
17/313679
Inventors:
- New Haven CT, US
Chungpin Herman CHEN - Madison CT, US
Hanqing DONG - Madison CT, US
Robert J. DUGUID - Glenmont NY, US
John A. GROSSO - Princeton Jct. NJ, US
Casey Keith JAGER - Bend OR, US
Venkata A. KATTUBOINA - Westford MA, US
Aditya Mohan KAUSHAL - Bend OR, US
Samuel Elliott KENNEDY - Bend OR, US
Rhys LLOYD - North Lanarkshire, GB
Miranda Annell NEESER - Bend OR, US
Yuping QIU - Princeton Junction NJ, US
Hayley REECE - Dalkeith, GB
Maxwell Marco REEVE - Guilford CT, US
Joseph P. REO - Riegelsville PA, US
Jerod ROBERTSON - Robbinsville NJ, US
Mohammad Mehdi ZAHEDI - Albany NY, US
Assignee:
Arvinas Operations, Inc. - New Haven CT
International Classification:
C07D 401/14
A61K 9/00
A61K 9/20
A61K 45/06
Abstract:
The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}methyl)piperidin-1-yl]pyridazine-3-carboxamide, referred to herein as Compound A:The present disclosure also relates methods of manufacturing and purifying the same, as well as intermediates useful in the synthesis of Compound A. The ultra-pure forms, polymorphs, amorphous forms, and formulations of Compound A can be used as therapeutic agents for the treatment of various diseases and conditions such as cancer.

Compositions And Methods For The Treatmentof Neurodegenerative And Other Diseases

View page
US Patent:
20200009118, Jan 9, 2020
Filed:
Feb 7, 2019
Appl. No.:
16/270022
Inventors:
- Sunnyvale CA, US
Mark W. Moore - San Anselmo CA, US
David K. Lyon - Bend OR, US
Casey K. Jager - Bend OR, US
Doug Lorenz - Bend OR, US
Corey Bloom - Bend OR, US
Kimberley Shepard - Bend OR, US
Assignee:
Glialogix, Inc. - Sunnyvale CA
International Classification:
A61K 31/4402
A61P 25/28
A61P 35/00
A61K 31/353
A61K 47/32
Abstract:
In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine, an ABCG2 inhibitor and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine and an ABCG2 inhibitor.

Formulations Of 4-Methyl-5-(Pyrazin-2-Yl)-3H-1,2-Dithiole-3-Thione, And Methods Of Making And Using Same

View page
US Patent:
20190209556, Jul 11, 2019
Filed:
Mar 12, 2019
Appl. No.:
16/351058
Inventors:
- Zug, CH
Barbara-Jean Anne Bormann-Kennedy - Wellfleet MA, US
Bomi Framroze - Menlo Park CA, US
Bret Berner - Half Moon Bay CA, US
Michael Edward Grass - Bend OR, US
Casey Keith Jager - Bend OR, US
Jay Corey Bloom - Bend OR, US
Mark Joseph Kastantin - Bend OR, US
International Classification:
A61K 31/497
A61K 47/32
A61K 47/38
Abstract:
This disclosure provides, among other things, compositions comprising quantities of oltipraz crystals, as well as method of making such compositions, and method of treating patients using such compositions.

Formulations Of 4-Methyl-5-(Pyrazin-2-Yl)-3H-1,2-Dithiole-3-Thione, Taste-Modified Formulations, And Methods Of Making And Using Same

View page
US Patent:
20190209557, Jul 11, 2019
Filed:
Mar 12, 2019
Appl. No.:
16/351122
Inventors:
- Zug, CH
Barbara-Jean Anne Bormann-Kennedy - Wellfleet MA, US
Bomi Framroze - Menlo Park CA, US
Bret Berner - Half Moon Bay CA, US
Michael Edward Grass - Bend OR, US
Casey Keith Jager - Bend OR, US
Jay Corey Bloom - Bend OR, US
Mark Joseph Kastantin - Bend OR, US
Romain Bachelard - Le Bar-sur-loup, FR
International Classification:
A61K 31/497
A61K 9/19
A61K 9/16
A61K 9/14
Abstract:
This disclosure provides, among other things, compositions comprising quantities of oltipraz crystals, as well as method of making such compositions, and method of treating patients using such compositions. Taste-modified compositions also are provided.

Compositions And Methods For The Treatmentof Neurodegenerative And Other Diseases

View page
US Patent:
20180110760, Apr 26, 2018
Filed:
Oct 20, 2017
Appl. No.:
15/789243
Inventors:
- Sunnyvale CA, US
Mark W. Moore - San Anselmo CA, US
David K. Lyon - Bend OR, US
Casey K. Jager - Bend OR, US
Doug Lorenz - Bend OR, US
Corey Bloom - Bend OR, US
Kimberly Shepard - Bend OR, US
Assignee:
Glialogix, Inc. - Sunnyvale CA
International Classification:
A61K 31/4402
A61K 31/353
A61K 47/32
A61P 25/28
A61P 35/00
Abstract:
In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine, an ABCG2 inhibitor and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine and an ABCG2 inhibitor.
Control profile
Casey K Jager from Bend, OR, age ~46 Get Report